Novartis Approaches Acquisition of Avidity Biosciences
Novartis, the Swiss pharmaceutical giant, is proposing to buy Avidity Biosciences at a price exceeding $70 per share.
Skip to main content
Novartis, the Swiss pharmaceutical giant, is proposing to buy Avidity Biosciences at a price exceeding $70 per share.
Novartis, the Swiss pharmaceutical giant, is proposing to buy Avidity Biosciences at a price exceeding $70 per share.